Prevention of Lens Epithelial Cell Growth In Vitro Using Mibefradil-Containing PLGA Micro Particles~!2008-04-23~!2008-05-24~!2008-06-12~!

Weidmann, Arne; Kwittner, Sabine; Beck, R.; Teller, Joachim; Jonas, Ludwig; Nebe, J. Barbara

doi:10.2174/1874364100802010112

Cited by 5 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its use in the prevention of PCO is based on the hypothesis that it inhibits the pathways mediating cell adhesion. The effect of mibefradil dihydrochloride was tested in primary human LECs obtained after cataract surgery and in a human lens cell line (HLE-B3) [43]. During the surgical procedure, fragments of the lens present on the anterior capsule were collected and cultured for 1-2 weeks.…”

Section: Disruption Of Cell Adhesionmentioning

confidence: 99%

Posterior Capsule Opacification: A Review of Experimental Studies

Konopińska

Młynarczyk

Dmuchowska

et al. 2021

JCM

View full text Add to dashboard Cite

Posterior capsule opacification (PCO) is the most common complication of cataract surgery. It causes a gradual deterioration of visual acuity, which would otherwise improve after a successful procedure. Despite recent advances in ophthalmology, this complication has not been eradicated, and the incidence of PCO can be as high as 10%. This article reviews the literature concerning the pathomechanism of PCO and examines the biochemical pathways involved in its formation and methods to prevent this complication. We also review the reported tests performed in cell cultures under laboratory conditions and in experimental animal models and in ex vivo human lens capsules. Finally, we describe research involving human eyes in the clinical setting and pharmacological methods that may reduce the frequency of PCO. Due to the multifactorial etiology of PCO, in vitro studies make it possible to assess the factors contributing to its complications and search for new therapeutic targets. Not all pathways involved in cell proliferation, migration, and contraction of the lens capsule are reproducible in laboratory conditions; moreover, PCO in humans and laboratory animals may be additionally stimulated by various degrees of postoperative reactions depending on the course of surgery. Therefore, further studies are necessary.

show abstract

Section: Disruption Of Cell Adhesionmentioning

confidence: 99%

Posterior Capsule Opacification: A Review of Experimental Studies

Konopińska

Młynarczyk

Dmuchowska

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Its use in the prevention of PCO is based on the hypothesis that it inhibits the pathways mediating cell adhesion. The effect of mibefradil dihydrochloride was tested in primary human LECs obtained after cataract surgery and in a human lens cell line (HLE-B3) (45). During the surgical procedure, fragments of the lens present on the anterior capsule were collected and subjected to cell culture for 1-2 weeks.…”

Section: Disruption Of Cell Adhesionmentioning

confidence: 99%

Posterior Capsule Opacification: A Review of Experimental Studies

Konopińska¹,

Romaniuk²,

Dmuchowska³

et al. 2021

Preprint

View full text Add to dashboard Cite

Posterior capsule opacification (PCO) is the most common complication of cataract surgery. It causes a gradual deterioration of visual acuity, which would otherwise remain improved after a successful procedure. Despite recent advances in ophthalmology, this complication has not been eradicated and the incidence of PCO can be as high as 10%. This article reviews the literature concerning the pathomechanism of PCO and examines the biochemical pathways involved in its formation and methods to prevent this complication. We also review the reported tests performed in cell cultures under laboratory conditions, in experimental animal models, and in ex vivo human lens capsules. Finally, we describe research involving human eyes in the clinical setting and pharmacological methods that may reduce the frequency of PCO. Due to the multifactorial eti-ology of PCO, in vitro studies make it possible to assess the factors contributing to its complica-tions and search for new therapeutic targets. Not all pathways involved in cell proliferation, mi-gration, and contraction of the lens capsule are reproducible in laboratory conditions; moreover, PCO in humans and laboratory animals may be additionally stimulated by various degrees of postoperative reactions depending on the course of surgery. Therefore, further studies are necessary.

show abstract

“…Ceftiofur is metabolized in the liver upon its administration, generating desfuroylceftiofur as a primary metabolite, which maintains its antimicrobial activity. While several reported studies have investigated the synthesis and characterization of PLGA microparticles loaded with antibiotics, only a few have tested the effectiveness and toxicological effects in vivo [ 9 – 11 ]. In this work, we present the synthesis and characterization of ceftiofur encapsulated in PLGA microparticles, the in vitro antibacterial activity, and the efficacy in rats infected with Salmonella Typhimurium.…”

Section: Introductionmentioning

confidence: 99%

Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles

et al. 2015

View full text Add to dashboard Cite

Drug delivery systems based on polymeric microparticles represent an interesting field of development for the treatment of several infectious diseases for humans and animals. In this work, we developed PLGA microparticles loaded with ceftiofur (PLGA-cef), a third- generation cephalosporin that is used exclusively used in animals. PLGA-cef was prepared by the double emulsion w/o/w method, and exhibited a diameter in the range of 1.5–2.2 μm, and a negative ζ potential in the range of -35 to -55 mV. The loading yield of PLGA-cef was ~7% and encapsulation efficiency was approximately 40%. The pharmacokinetic study demonstrated a sustained release profile of ceftiofur for 20 days. PLGA-cef administrated in a single dose was more effective than ceftiofur non-encapsulated in rats challenged with S. Typhimurium. The in vivo toxicological evaluation showed that PLGA-cef did not affect the blood biochemical, hematological and hemostasis parameters. Overall, the PLGA-cef showed slow in vivo release profile, high antibacterial efficacy, and low toxicity. The results obtained supports the safe application of PLGA-cef as sustained release platform in the veterinary industry.

show abstract

Prevention of Lens Epithelial Cell Growth In Vitro Using Mibefradil-Containing PLGA Micro Particles~!2008-04-23~!2008-05-24~!2008-06-12~!

Cited by 5 publications

References 34 publications

Posterior Capsule Opacification: A Review of Experimental Studies

Posterior Capsule Opacification: A Review of Experimental Studies

Posterior Capsule Opacification: A Review of Experimental Studies

Preclinical Development and In Vivo Efficacy of Ceftiofur-PLGA Microparticles

Contact Info

Product

Resources

About